A novel rapamycin cream formulation improves facial angiofibromas associated with tuberous sclerosis complex: a double-blind randomized placebo-controlled trial
Journal
The British journal of dermatology
Journal Volume
189
Journal Issue
5
Date Issued
2023-10-25
Author(s)
Aitken, Phillip
Stanescu, Ioana
Boddington, Laura
Mahon, Caroline
Fogarasi, Andras
Ivars, Marta
Moreno-Artero, Ester
Trauner, Doris
DeRoos, Steven T
Jancic, Jasna
Nikolic, Milos
Balážová, Patrícia
Price, Harper N
Hadzsiev, Kinga
Riney, Kate
Stapleton, Stacie
Tollefson, Megha M
Bauer, Derek
Pinková, Blanka
Atkinson, Hartley
Abstract
Facial angiofibromas (FAs) are a major feature of tuberous sclerosis complex (TSC). Topical rapamycin can successfully treat FAs. A new stabilized cream formulation that protects rapamycin from oxidation has been developed in 0.5% and 1% concentrations.
SDGs
Type
journal article